The use of platelet rich plasma in the management of medication-related osteonecrosis of the jaws: a cohort study

Francesco Ricotta, Carlotta Del Principe¹, Giovanni Leandro Arcangeli¹

¹ University of Bologna

Funding: The author(s) received no specific funding for this work.
Potential competing interests: The author(s) declared that no potential competing interests exist.

Abstract

Medication-related osteonecrosis of the jaw (MRONJ) is an adverse drug reaction that occurs in a very different ways and affects patients with complex medical histories. The objective of this study is to evaluate the prognosis of surgically treated drug-related osteonecrotic lesions and to verify whether the platelet concentrates used during the surgical procedure can improve the prognosis. The study was performed by analyzing a sample of 64 patients with medication-related osteonecrosis of the maxillary bones, in which 79 lesions were diagnosed and surgically treated at the S. Orsola-Malpighi Polyclinic in Bologna. The lesions treated with PRP showed a lower tendency to relapse compared to its non-use, the probability of recurrence.

In conclusion, this study demonstrates that treatment with PRP may have positive effects in the therapy of Medication-Related Osteonecrosis of the Jaw (MRONJ).

Background: Medication-related osteonecrosis of the jaw (MRONJ) is an adverse drug reaction that occurs in a very different ways and affects patients with complex medical histories. The symptoms and signs consist of pain, bone exposure, inflammation of the surrounding soft tissue swelling, and secondary infection or drainage. Decisions about treatment are based on factors such as age, sex, the stage of the disease, the severity of the BRONJ, the size and site of the lesion, exposure to drugs, and the presence of coexisting diseases. The objective of this study is to evaluate the prognosis of surgically treated drug-related osteonecrotic lesions and to verify whether the platelet concentrates used during the surgical procedure can improve the prognosis.

Materials and Methods: The study was performed by analyzing a sample of 64 patients with medication-related osteonecrosis of the maxillary bones, in which 79 lesions were diagnosed and surgically treated at the S. Orsola-Malpighi Polyclinic in Bologna. Subjects treated only with drug therapy and subjects with osteoradionecrosis were excluded. The patients were then divided into two parallel cohorts: one made up of subjects treated using platelet concentrates, and one in which the patients were operated on without their use. Of these subjects, the relapse and the time in which it occurs was examined. A descriptive analysis of the entire sample was performed, using the appropriate measures of central tendency and dispersion (mean and standard deviation) and frequency. The Cox mixed effects model to determine the hazard ratio (HR) of relapse between the two cohorts, adding for the following confounding factors: age, sex, type of surgery, type of antiresorptive drug, diabetes and other metabolic disorders and AAOMS stage.

Results: The average documented follow-up is 19 months and the antiresorptive drug taken were zoledronate in 43 patients (67%), alendronate in 10 patients (15%), ibandronate in 5 patients (8%), risedronate in 5 patients (5%) and denosumab in 3 patients (5%). Referring to the AAOMS staging system described in 2014, of the 79 surgically treated lesions, 48 were diagnosed in stage 2 (61%), 16 in stage 3 (20%) and 15 in stage 1 (19%). Most of the lesions were located in the mandible (75%). Of the 79 injuries affecting the maxillary bones, 61 (77%) were treated with conservative surgery (26 treated with the help of PRP) and 18 (23%) with resective surgery (9 of them treated with the help of PRP). Of the 79 surgically treated lesions, 24 episodes (30%) of relapse were documented. In 35 cases platelet concentrates were used as adjuvant therapy to surgery, of these 9 relapsed (26%) unlike 15 (74%) who did not relapse. When they aren’t used, relapses occurred in 15 cases (34%).
In resective surgery (18 cases), PRP was associated in 9 cases, with 2 recurrence episodes (22%). In the remaining 9 cases not associated with resective surgery, there were 5 relapses (55.6%).

In the 61 conservative surgeries performed, platelet concentrates were used 26 times, with 7 relapses (27%). In the remaining 35 cases, however, there were 10 relapses (28.6%).

According to the 2014 AAOMS staging:
- Stage 1: 15 lesions, the use of platelet concentrates was implicated in 6 cases (no relapse episodes 0%). In the 9 cases where they were not used, there were 2 recurrence episodes (22%).
- Stage 2: 48 lesions, platelet concentrates were used 21 times with 9 relapse episodes (43%) and 12 non-relapse episodes (57%). While in the 27 cases of non-use, relapses were found in 8 cases (30%).
- Stage 3: 16 lesions, platelet concentrates were implicated 8 times (no relapses, 0%). In the 8 remaining cases, there were 5 relapses (63.5%), and 3 episodes without relapse (37.5%).

The probability of relapse of osteonecrotic lesions 1 month after surgery was found to be 13%, 3 months 19.3%, 6 months 29.2%, 12 months 33.4% and 35.8% at 50 months.

The lesions treated with PRP showed a lower tendency to relapse compared to its non-use, the probability of recurrence at 1 month after surgery was found to be 9%, at 3 months 11.4%, at 6 months 21.3%, 24.6% at 12 months and 28.2% at 50 months. On the other hand, the lesions treated without the aid of the PRP, showed a probability of recurrence at 1 month of 16%, at 3 months of 26%, at 6 months of 35.3%, at 12 months of 42.5% and always 42.5% at 50 months.

From the results of the Cox model, it was highlighted how the risk of relapse for lesions treated with the aid of PRP was found to be statistically lower than the lesions not treated with PRP (Hazard Ratio 0.35; P = 0.041).

Discussion:
The treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ) is much debated topic in the scientific community and numerous studies have been performed in this regard.

Today the surgical approach is not a secondary choice, but rather a primary therapeutic option even in the early stages of MRONJ, with the goal of stopping the progression of the disease in the most effective and early way possible. In fact, the conservative approach appears to be useful only in a limited number of cases and especially poorly effective in the advanced stages of MRONJ.

Our study considered the treatment of 79 osteonecrotic lesions through resective surgery and conservative surgery, with or without the aid of platelet concentrates, finding 24 episodes (30%) of relapses with an average follow-up of 19 months. Evaluating reviews of the literature available on MRONJ surgical therapy shows that most of clinical relapses occur within 6 months, but it is important to underline that a significant number of relapses occur within 1 year of treatment, whatever the surgical therapy used. Moreover many studies have a follow-up of 6 months or less, thus overestimating the treatment adopted.

For this reason it is important not only to monitor the patient but also to decrese the success of the therapy only when mucosal healing is maintained in the absence of clinical and radiographic signs and symptoms 1 year after the completion of the surgical treatment.

Our study shows that the risk of relapse for lesions treated with the aid of platelet concentrates is lower than for lesions treated without, that is confirmed by several studies documented in the literature.

However, in our case series, particularly in patients with stage II MRONJ, we had a lower number of recurrences in cases treated without the aid of PRP than in those treated with PRP.

These results suggest that surgery has a fundamental role in the treatment of this pathology, of which PRP represents a valuable aid. Although PRP plays an important role in bone biology by releasing high amounts of growth factors, improving bone repair, stimulating angiogenesis and accelerating the healing, it is still unclear why we obtained these results in stage II patients MRONJ. According to other results, PRP appears to be a therapeutic choice in combination with antibiotic therapy and conventional surgery despite there is no definitive protocol for its use. Nevertheless, it is known in literature that therapeutic success depends on several factors such as the location of the lesion, the size of the lesion or the moment of diagnosis, so that, despite they are quite encouraging results in the treatment of this pathology, more studies are needed to demonstrate the true efficacy of the therapy indeed our results are not sufficient to prove its effectiveness.

There are no published scientific data to sufficiently support any specific treatment protocol, including the use of PRP together with surgical debridement, for the management of MRONJ. Randomized controlled clinical trials of the use of PRP are needed.

Conclusions:
In the treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ), the surgical approach certainly guarantees satisfactory success rates, as widely documented in the literature. This outcome seems to be confirmed by the positive effect of PRP in the treatment of these problems as an aid to the surgery itself. These platelet concentrates in fact promote healing and reduce the risk of relapse. However, further studies are needed in this regard to confirm the effectiveness and establish a definitive use protocol.

References
1. Barrera BA, Wilton L, Harris S, Shakir SA. Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. Dec 2005;16(12):1989-1998.
2. Berenson JR, Lipton A. Bisphosphonates in the treatment of malignant bone disease. Annu Rev Med. 1999;50:237-248. doi:10.1146/annurev.med.50.1.237
3. Do WS, Park JK, Park MI, Kim HS, Kim SH, Lee DH. Bisphosphonate-induced Severe Hypocalcemia - A Case Report -. J Bone Metab. 2012;19(2):139-145. doi:10.11005/jbm.2012.19.2.139
4. Frediani B, Giusti A, Bianchi G, Dalle Carbonare L, Malavolta N, Cantarini L, Saviola G, Molfetta L. Clodronate in the management of different musculoskeletal conditions. Minerva Med. 2018 Aug;109(4):300-325.
5. Girgis C.M: Integrated therapies for osteoporosis and sarcopenia: from signaling pathways to clinical trias. Calcified Tissue International, 96, 243-55; 2015.
6. Goodman & Gilman Le basi farmacologiche della terapia; Zanichelli; XII edizione (2012) a cura di Brunton L., Chabner B.A., Knollmann B.C.

7. M Schiodt, J Reibel, P Oturai, T Kofod Comparison of nonexposed and exposed bisphosphonate-induced osteonecrosis of the jaws: a retrospective analysis from the Copenhagen cohort and a proposal for an updated classification system Oral Surg Oral Med Oral Pathol Oral Radiol, 117 (2014), pp. 204-213

8. Marx R.E: L’Osteonecrosi dei Mascellari da Bisfosfonati; Storia, Eziologia, Prevenzione e Trattamento dell’osteonecrosi indotta dai bisfosfonati per via orale e per via endovenosa; Quintessenza Edizioni; 2009.

9. Papapetrou PD. Bisphosphonate-associated adverse events. Hormones (Athens). 2009;8(2):96-110. doi:10.14310/horm.2002.1226

10. Reid IR. Osteoporosis treatment: focus on safety. Eur J Intern Med. 2013;24(8):691 - 697. doi:10.1016/j.ejim.2013.03.012

11. Ross, J.R., Saunders, Y., Edmonds, P.M., Patel, S., Broadley, K.E., Johnston, S.R., 2003. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ (Clinical research ed.) 327, 469.

12. Russell R.G.G., Watts N.B., Ebetino F.H., Rogers M.J: Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008 Jun;19(6):733-59. doi: 10.1007/s00198-007-0540-8.

13. S Fedele, G Bedogni, M Scoletta, et al. Up to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed Br J Oral Maxillofac Surg, 53 (2015), pp. 13-17

14. A. Del Vecchio, F. Libotte, G. Palaia, G. Tenore, A. Galanakis, R. Kornblit, U. Romeo. Il laser a Erbio in odontoiatria: applicazioni e vantaggi. 2013.

15. American Association of Oral and Maxillofacial Surgeons: American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws. J. Oral Maxillofac Surg 65:369-376, (2007).

16. Campisi G., Bedogni A., Di Fede O., Vescovi P., Fusco V., Lo Muzio L.: Osteonecrosi dei mascellari associata a bifosfonati, Denosumab, e farmaci antiangiogenetici nei pazienti oncologici e osteoporotici: diagnosi e terapia. Dental Cadmos, 9, 566-589 (2013).

17. Campisi G., Di Fede O., D’Alessandro N., Argo A: PROMaF, Documento informativo ad ampia divulgazione per l’approssimamento dell’osteonecrosi dei mascellari relata all’uso di farmaci (bisfosfonati, anti-riassorbiviti e farmaci a target biologico), 2014; http://www.policlinico.pa.it/portal/pdf/news/2014/PROMaF/PROMaFxOperatoriSanitari-dic2014.pdf .

18. Fleish H. bisphosphonates in bone disease. From the laboratory to the patient, Third Edition. The Parthenon Publishing Group 1997. New York.

19. Marx R.E: Pamidronate (Aredia) and Zoledronate (Zometa) induced avascular necrosis of the jaw: a growing epidemic. Journal Oral Maxillofac. Surg, 61 (9), 1115-1117 (2003).

20. Ruggiero S.L., Dodson T.B., Assael L.A., Landersberg R., Marx R.E., Mehrotra B: American Association of Oral and Maxillofacial Surgeons: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw. 2009 update. J. Oral Maxillofac. Surg., 67 -suppl. 5 (2009).

21. Ruggiero S.L., Dodson T.B., Fantasia J., Goodday R., Aghaloo T., Mehrotra B., O’Ryan F: American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014 Oct;72(10):1938-56.

22. Russell RGG, Rogers MJ. Bisphosphonates: from laboratory to the clinic and back again. Bone 1999; 25:97-106.

23. Vescovi V: Osteonecrosi dei mascellari e bisfosfonati. Terapia odontoiatrica e prevenzione; Tecniche Nuove; 2008.